United States - English - NLM (National Library of Medicine)

exelan pharmaceuticals, inc. - lanreotide acetate (unii: ieu56g3j9c) (lanreotide - unii:0g3de8943y) - lanreotide injection is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. the goal of treatment in acromegaly is to reduce growth hormone (gh) and insulin growth factor-1 (igf-1) levels to normal. lanreotide injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (gep-nets) to improve progression-free survival. lanreotide injection is contraindicated in patients with history of a hypersensitivity to lanreotide. allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide [see adverse reactions (6.3)] . risk summary limited available data based on postmarketing case reports with lanreotide injection use in pregnant women are not sufficient to determine a drug-associated risk of adverse dev

United States - English - NLM (National Library of Medicine)

cipla usa inc. - lanreotide acetate (unii: ieu56g3j9c) (lanreotide - unii:0g3de8943y) - lanreotide injection is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. the goal of treatment in acromegaly is to reduce growth hormone (gh) and insulin growth factor-1 (igf-1) levels to normal. lanreotide injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (gep-nets) to improve progression-free survival. lanreotide injection is contraindicated in patients with history of a hypersensitivity to lanreotide. allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide [ see adverse reactions (6.3)] . risk summary limited available data based on post-marketing case reports with lanreotide use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmenta

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lanreotide acetate 149.4mg equivalent to lanreotide 120 mg - solution for injection - 120 mg - active: lanreotide acetate 149.4mg equivalent to lanreotide 120 mg excipient: glacial acetic acid water for injection - treatment of acromegaly when circulating levels of gh and igf-1 remain abnormal after surgery and/or radiotherapy, or in patients who are dopamine agonist treatment refractory. treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lanreotide acetate 77.9mg equivalent to lanreotide 60 mg - solution for injection - 60 mg - active: lanreotide acetate 77.9mg equivalent to lanreotide 60 mg excipient: glacial acetic acid water for injection - treatment of acromegaly when circulating levels of gh and igf-1 remain abnormal after surgery and/or radiotherapy, or in patients who are dopamine agonist treatment refractory. treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lanreotide acetate 113.6mg equivalent to lanreotide 90 mg - solution for injection - 90 mg - active: lanreotide acetate 113.6mg equivalent to lanreotide 90 mg excipient: glacial acetic acid water for injection - treatment of acromegaly when circulating levels of gh and igf-1 remain abnormal after surgery and/or radiotherapy, or in patients who are dopamine agonist treatment refractory. treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 66.67 mg (equivalent: lanreotide, qty 60 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 133.33 mg (equivalent: lanreotide, qty 120 mg) - injection, solution - excipient ingredients: water for injections; glacial acetic acid - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 100 mg (equivalent: lanreotide, qty 90 mg) - injection, solution - excipient ingredients: water for injections; glacial acetic acid - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate, quantity: 149.4 mg (equivalent: lanreotide, qty 125.5 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - somatuline autogel is indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory -the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours -the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate, quantity: 113.6 mg (equivalent: lanreotide, qty 95.4 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - somatuline autogel is indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory -the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours -the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.